Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2

Neutral

AI Analysis

Summary

Eli Lilly announced an acquisition of Atai Beckley for up to $3.8 billion, signaling validation in the psychedelics space, while Novartis and Roche report Q2 earnings and FDA continues to navigate its policy on publishing complete response letters.

Outcome Details

Eli Lilly acquiring Atai Beckley for up to $3.8 billion

Importance:6/10

Sentiment:

0.20

earningsacquisitionpsychedelicsFDACRLIPO

Related Companies

$LLY $ATAI $NVS $RHHBY

Read the original article

Published by BioSpace on July 22, 2026 11:18 AM

Read Original